T-Cell-Monocyte Communication in Type 2 Diabetes
Li et al. 2025 used CellChat to compare inferred communication between T-cell and monocyte subtypes across T2D subtypes A-C and healthy controls.
Communication Intensity
- Li et al. 2025 report subtype A had 1418 inferred interactions and interaction strength 0.995.
- Li et al. 2025 report subtype B had 1841 inferred interactions and interaction strength 1.133, the highest among the groups.
- Li et al. 2025 report subtype C had 1537 inferred interactions and interaction strength 0.93.
- Li et al. 2025 report healthy controls had 1531 inferred interactions and interaction strength 0.793.
- Li et al. 2025 interpret these values as stronger cellular interactions in T2D than healthy controls.
Pathway Patterns
- Li et al. 2025 report MHC-I signaling contributed broadly across all three T2D subtypes and mediated nearly all communication between T-cell and monocyte subtypes.
- Li et al. 2025 report subtype A showed the highest MHC-I pathway activity, followed by healthy controls, with subtype C lowest.
- Li et al. 2025 report subtype B showed broad pathway mediation through CD30, CD48, TGF-beta, IFN-II, TNF, and CCL signaling.
- Li et al. 2025 report that in subtype B, TNF signaling involved intermediate and non-classical monocytes communicating with monocyte and T-cell subtypes.
- Li et al. 2025 describe subtype C TNF signaling as restricted to non-classical monocytes communicating with other monocyte and T-cell subtypes.
- Li et al. 2025 report VISFATIN signaling was present in subtype C and healthy controls and was limited to T-cell-to-T-cell communication.
Manuscript Relevance
- The paper supports a model in which T2D PBMC immune remodeling involves altered immune-cell crosstalk, not only altered cell proportions.
- MHC-I pathway dominance creates a bridge to antigen-presentation language already present in t2d-monocyte-inflammatory-signature.
- CellChat results are inferred ligand-receptor communication and should be framed as computational interaction evidence, not direct functional validation.
Links
- li-2025-immunometabolic-alterations-t2d
- t2d-t-cell-immunometabolic-subtypes
- t2d-monocyte-inflammatory-signature
- pbmc-immune-changes-in-type-2-diabetes